Advertisement

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children

  • C. Hays
  • Q. Vermee
  • A. Agathine
  • A. Dupuis
  • E. Varon
  • C. Poyart
  • M.-C. Ploy
  • J. Raymond
  • and the ORP Ile de France Ouest
Original Article

Abstract

The purpose of this investigation was to describe the evolution of serotypes and antibiotic susceptibility of Streptococcus pneumoniae strains isolated from both adults and children from the same population area with invasive pneumococcal disease (IPD) or acute otitis media (AOM), 5 years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). From 2009 to 2015, 839 strains of S. pneumoniae strains were collected (481 from adults and 358 from children). Serotyping by latex antisera and molecular methods was performed. Antimicrobial susceptibility was tested. Compared to 2009, the total number of strains isolated in 2015 decreased in children (263 vs. 53, respectively) and in adults (220 vs. 131, respectively). Serotype coverage of PCV13 for IPD decreased significantly in adults from 67.7% (149/220) to 25.2% (33/131) and in children from 75.1% (61/81) to 18.5% (5/27). Especially, serotypes 1, 7F and 19A decreased significantly in children, while serotypes 7F and 19A decreased significantly in adults. PCV13 serotypes involved in AOM decreased significantly over the 5-year period, from 85.7% (156/182) to 38.5% (10/26), and were more susceptible to penicillin, amoxicillin and cefotaxime, p < 0.05. Serotypes 8, 9N and 10A seemed to emerge in adults, whereas any serotype prevalence was observed in children. Between 2009 and 2015, the introduction of PCV13 has resulted in a significant decrease of the number of S. pneumoniae strains isolated from IPD in children as in adults. It highlights a strong herd effect of vaccination in adults.

Keywords

Cefotaxime Acute Otitis Medium Invasive Pneumococcal Disease Herd Effect Recurrent Acute Otitis Medium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We sincerely thank all the members of the ORP Ile de France Ouest for the data collection: G. Arlet, L. Armand-Lefevre, E. Benabib, T. Billard-Pomares, G. Blanchard, E. Cambau, E. Carrer-Causseret, C. Doit, A. Claudinon, F. Doucet-Populaire, Agnès Ferroni, C. Freneaux, C. Guillet-Caruba, H. Lecuyer, V. Leflon-Guibout, M. Leneveu, Françoise Leturdu, A.C. Maherault, D. Moissenet, A. Mbadi, L. Raskine, F. Richardin, V. Sivadon-Tardy, C. Souffi, J. Tankovic, C. Verdet.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

For this type of retrospective study, informed consent is not required.

Ethical approval

Isolates were stored and data were anonymised. Therefore, development of the typing scheme on stored and anonymised isolates in a retrospective study did not require ethical approval.

Funding

No grant was received for this study.

References

  1. 1.
    Bogaert D, De Groot R, Hermans PWM (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154CrossRefPubMedGoogle Scholar
  2. 2.
    De Lencastre H, Tomasz A (2002) From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 50:75–81CrossRefPubMedGoogle Scholar
  3. 3.
    AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 59:591–603PubMedPubMedCentralGoogle Scholar
  4. 4.
    Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5:83–93CrossRefPubMedGoogle Scholar
  5. 5.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2015) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33:359–66CrossRefPubMedGoogle Scholar
  6. 6.
    Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D (2008) Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill 13(35): pii: 18962Google Scholar
  7. 7.
    Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746CrossRefPubMedGoogle Scholar
  8. 8.
    Black S, Shinefield H, Baxter B, Austrian R, Elvin L, Hansen J, Lewis E, Fireman B (2006) Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24:S79–S80Google Scholar
  9. 9.
    Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG; Active Bacterial Core Surveillance Team (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–2051CrossRefPubMedGoogle Scholar
  10. 10.
    Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS (2007) Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25:5390–5398CrossRefPubMedGoogle Scholar
  11. 11.
    Dortet L, Ploy MC, Poyart C, Raymond J; ORP Ile de France Ouest (2009) Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 65:49–57CrossRefPubMedGoogle Scholar
  12. 12.
    Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E, Raymond J; ORP Ile de France Ouest (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30:1511–1519CrossRefPubMedGoogle Scholar
  13. 13.
    Hurmic O, Grall N, Al Nakib M, Poyart C, Grondin S, Ploy MC, Varon E, Raymond J; ORP Ile de France-Ouest Network (2014) Evidence of a clonal expansion of Streptococcus pneumoniae serotype 19A in adults as in children assessed by the DiversiLab® system. Eur J Clin Microbiol Infect Dis 33:2067–2073Google Scholar
  14. 14.
    Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502CrossRefPubMedGoogle Scholar
  15. 15.
    Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784–1792CrossRefPubMedGoogle Scholar
  16. 16.
    Hsu KK, Pelton SI (2003) Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2:619–631CrossRefPubMedGoogle Scholar
  17. 17.
    Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193:1487–1494CrossRefPubMedGoogle Scholar
  18. 18.
    Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG; Active Bacterial Core Surveillance Team (2006) Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44:999–1017CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB (2015) Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012. JAMA Pediatr 169(7):646–652CrossRefPubMedGoogle Scholar
  20. 20.
    Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, Rahav G, Dagan R; IAIPD group (2015) Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33(9):1135–1142CrossRefPubMedGoogle Scholar
  21. 21.
    Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS (2015) Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45(6):1632–1641CrossRefPubMedGoogle Scholar
  22. 22.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2014) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33(2):359–366CrossRefPubMedGoogle Scholar
  23. 23.
    Janoir C, Lepoutre A, Gutmann L, Varon E (2016) Insight into resistance phenotypes ofemergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolatedfrom invasive disease after 13-valent pneumococcal conjugate vaccine implementationin France. Open Forum Infect Dis 3(1):ofw020Google Scholar
  24. 24.
    Pai R, Gertz RE, Beall B (2006) Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 44:124–131CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ (2014) Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 33:637–642CrossRefPubMedGoogle Scholar
  26. 26.
    Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML (2014) Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2:155–158CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, Gabastou JM, Camou T; Uruguayan SIREVA II Group (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One 9:e112337CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R (2014) Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 32:3452–3459CrossRefPubMedGoogle Scholar
  29. 29.
    Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, Chardon H, Cremniter J, Croizé J, Dalmay F, Demachy MC, Fosse T, Grelaud C, Hadou T, Hamdad F, Koeck JL, Luce S, Mermond S, Patry I, Péchinot A, Raymond J, Ros A, Segonds C, Soullié B, Tandé D, Vergnaud M, Vernet-Garnier V, Wallet F, Gutmann L, Ploy MC, Lanotte P (2015) Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. Clin Microbiol Infect 21:35–42Google Scholar
  30. 30.
    Grau I, Ardanuy C, Cubero M, Benitez MA, Liñares J, Pallares R (2016) Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect 72:439–449CrossRefPubMedGoogle Scholar
  31. 31.
    van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 10(7):e0131494CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 15:207CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15:419CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections (2016) Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol 7:1616CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sá-Leão R, Pinto F, Aguiar S, Nunes S, Carriço JA, Frazão N, Gonçalves-Sousa N, Melo-Cristino J, de Lencastre H, Ramirez M (2011) Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol 49:1369–1375CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Varon E, Cohen R, Béchet S, Doit C, Levy C (2015) Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine 33:6178–6185CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • C. Hays
    • 1
  • Q. Vermee
    • 1
  • A. Agathine
    • 1
  • A. Dupuis
    • 1
  • E. Varon
    • 2
  • C. Poyart
    • 1
  • M.-C. Ploy
    • 3
  • J. Raymond
    • 1
  • and the ORP Ile de France Ouest
  1. 1.University Paris 5, Hôpital Cochin, BacteriologieParisFrance
  2. 2.University Paris 5, Hôpital Georges Pompidou, CNR PneumocoquesParis 15France
  3. 3.Observatoire Regional des PneumocoquesLaboratoire de Bactériologie-Virologie-Hygiène, CHU Dupuytrein87042 LimogesFrance

Personalised recommendations